Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

Now Viewing

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment discusses challenges in predicting and mitigating treatment-related adverse events with adjuvant immunotherapy for melanoma.

Dr Khushalani states that being able to identify patients at high toxicity risk with checkpoint inhibitors would be ideal. Factors that raise caution for toxicity include underlying autoimmune disorders like rheumatoid arthritis that could be exacerbated. He would also have thorough discussions about using adjuvant checkpoint blockade in transplant patients given the risks of severe or chronic toxicity and need for long-term replacement therapies.

He notes that because available adjuvant approaches improve relapse-free but not yet overall survival in melanoma, patients and doctors must weigh whether that potential benefit outweighs quality-of-life risks, considering relapse patterns if observed initially (eg, regional nodes versus distant sites). Ultimately, deciding on adjuvant therapy requires an in-depth shared decision-making process with patients.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.